Clinical Chemistry AACC Online Job Center
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Clinical Chemistry 46: 1796-1803, 2000;
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacoby, E. S.
Right arrow Articles by Iles, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacoby, E. S.
Right arrow Articles by Iles, R. K.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism
(Clinical Chemistry. 2000;46:1796-1803.)
© 2000 American Association for Clinical Chemistry, Inc.


Articles

Determination of the Glycoforms of Human Chorionic Gonadotropin ß-Core Fragment by Matrix-assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry

Eli S. Jacoby1, Andrew T. Kicman2, Paul Laidler2 and Ray K. Iles1,a

1 The Williamson Laboratory, Department of Obstetrics and Gynaecology, St. Bartholomew’s & the Royal London School of Medicine and Dentistry, West Smithfield, London EC1A 7BE, United Kingdom.

2 The Drug Control Centre, King’s College London, Franklin-Wilkins Building, 150 Stamford St., London SE1 8WA, United Kingdom.
a Author for correspondence. Fax 44-020-7601-7050; e-mail r.k.iles{at}mds.qmw.ac.uk


   Abstract
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Background: Metabolism of human chorionic gonadotropin (hCG) in the serum and kidney yields the terminal urinary product hCG ß-core fragment (hCGßcf), comprising two disulfide-linked peptides (ß6-ß40 and ß55-ß92) of which one (ß6-ß40) retains truncated N-linked sugars. Hyperglycosylated hCGßcf may indicate choriocarcinoma or Down syndrome, but the glycosylation profile of hCGßcf has not been thoroughly evaluated.

Methods: hCGßcf, purified from pregnancy urine, was reduced by "on-target" dithiothreitol (DTT) reduction and analyzed by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS). The mass ([M+H]+) of the primary sequence of the glycosylated peptide ß6-ß40 was subtracted from the m/z values of the discrete peaks observed to give the masses of the carbohydrate moieties. Carbohydrate structure was predicted by sequentially subtracting the masses of the monosaccharide residues corresponding to N-linked carbohydrates of the hCG ß-subunit reported in the literature.

Results: Mass spectra of hCGßcf revealed a broad triple peak at m/z 8700–11300. After reduction, the triple peak was replaced by a discrete set of peaks between m/z 4156 and 6354. A peak at m/z 4156.8 corresponded to the nonglycosylated peptide (ß55-ß92). The remaining nine peaks indicated that urinary hCGßcf comprises a set of glycoforms smaller and larger than the trimannosyl core.

Conclusions: hCGßcf comprises a wider set of glycoforms than reported previously. Peaks of highest mass indicate evidence of hyperglycosylated carbohydrate moieties. The data support previous reports that hCGßcf oligosaccharides lack sialic acid and galactose residues. No indication was found of a ß6-ß40 peptide that was entirely devoid of carbohydrate.


   Introduction
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
The heterodimeric placental hormone human chorionic gonadotropin (hCG)1 is a widely studied member of the glycoprotein hormone family that includes luteinizing hormone, thyroid-stimulating hormone, and follicle-stimulating hormone. Each consists of a common {alpha} subunit and a unique ß subunit that confers specific hormonal activity. hCG sustains early pregnancy by binding luteinizing hormone receptors at the corpus luteum surface and stimulating progesterone secretion until the placenta is able to carry out this function itself. In addition to being universally used as an early marker of pregnancy, hCG is monitored in sports drug testing (1). The hCG ß-subunit (hCGß) is also a marker of various epithelial and gestational trophoblast carcinomas (2)(3), where it may exert independent stimulatory activity (4)(5). The precise structure of hCG has been well characterized by HPLC-mass spectrometry (6)(7) and by crystallographic analysis (8)(9). Peptide mass mapping by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS), using trypsin for digestion, has also been found to be a suitable technique for the identification of hCG and its subunits (10)(11).

hCG, in common with other glycoprotein hormones, is characterized by sugar moieties on both subunits that determine receptor affinity and metabolic clearance. The currently accepted structural model of the N-linked carbohydrates found on hCGß is of a complex biantennary moiety terminating in sialic acid based on a trimannosyl core (12). Despite the model, wide carbohydrate heterogeneity has been found. Mono-, bi-, and triantennary N-linked sugars occur in hCGß in both normal and abnormal pregnancies as well as in choriocarcinomas (12)(13)(14)(15)(16)(17). An increase in the triantennary form seems to be a feature indicative of an abnormal state and may be of diagnostic value. In normal pregnancies, Elliott et al. (14) found that the biantennary form accounted for 76.5% of the N-linked oligosaccharide content of urinary hCGß, that 21.6% was triantennary, and that the remainder was monoantennary (Fig. 1 ). In gestational choriocarcinoma, by contrast, the triantennary content accounted for up to 63.6% of the total. A similar increase in hCG hyperglycosylation has been detected in Down syndrome by Cole et al. (18). Indeed, an ELISA for hyperglycosylated hCG has been developed based on a monoclonal antibody raised to the hyperglycosylated variant (19)(20). Prenatal diagnostic testing of maternal urine based on this ELISA is claimed to detect up to 97% of Down syndrome cases with a 5% false-positive rate when modeled with values of other markers (21).



View larger version (22K):
[in this window]
[in a new window]
 
Figure 1. Structures of the asialo asparagine-linked oligosaccharides of the hCGß subunit from normal pregnancy, hydatidiform mole, choriocarcinoma (I, III, and IV, respectively), and gestational diabetes (II).

Adapted from Elliott et al. (14).

Similarly, carbohydrate heterogeneity remains in the terminal urinary degradation product of the ß-subunit, the hCG ß-core fragment (hCGßcf). This core fragment has a primary structure of 73 amino acids, consisting of two polypeptides: ß6-ß40 and ß55-ß92, joined by four cystine residues (Fig. 2 ). Only the ß6-ß40 chain is glycosylated, retaining the two complex N-glycans linked to asparagine residues 13 and 30. However, as a consequence of metabolism, these branched chain carbohydrates are truncated. Various studies of the carbohydrate structure of hCGßcf using a combination of immunoaffinity, gel-filtration, and ion-exchange chromatography, glycosidase digestion, hydrazinolysis, and periodate oxidation have been reported (22)(23)(24)(25)(26). A population of shortened mono- and biantennary carbohydrate cores has been suggested, which may or may not be fucosylated (22). There is disagreement over whether these moieties possess sialic acid or galactose residues, although there is some evidence that they do extend beyond the trimannosyl cores (24). In an attempt to help resolve this disagreement, we investigated the structural variation in these oligosaccharide moieties, using an alternative approach that incorporates analysis by MALDI-TOF MS.



View larger version (11K):
[in this window]
[in a new window]
 
Figure 2. Schematic diagram of the primary amino acid sequence of hCGßcf, showing positions of disulfide bonds and N-linked carbohydrates.

MALDI-TOF MS is a powerful tool for determining the mass of macromolecules, as first reported by Karas and Hillenkamp (27), yielding signals that correspond mainly to singly charged molecular ions. Chemical or enzymatic cleavage of posttranslationally modified proteins, followed by MALDI-TOF MS analysis, has been used for the purpose of structural characterization. Exoglycosidase digestion with MALDI-TOF MS analysis has been used to elucidate carbohydrate sequences and composition of glycoproteins (28). Nonetheless, at first glance, this approach appears to be overcomplicated for investigating the glycoforms of hCGßcf, particularly because the branch chain sequence is unlikely to be affected by metabolism of the ß-subunit, albeit that the chain is truncated. Indeed, exoglycosidase digestion could confound interpretation of results because absolute specificity for one substrate is rare and this may possibly lead to the presence of artifacts. However, direct analysis of hCGßcf by low-resolution MALDI-TOF MS is not sufficiently discriminating to identify individual glycoforms because of the lack of resolution between them. A simple but potentially useful approach could be to reduce the disulfide bonds, e.g., with DTT, to yield the two separate polypeptide chains before analysis. Separation of the ß55-ß92 chain, which is of no diagnostic value, from the ß6-ß40 chain is advantageous because the overall masses of the glycoproteins being analyzed are reduced, which is conducive to discriminating between them. The mass of each glycosylation variant on the ß6-ß40 chain can then be determined by calculating the difference in mass between each peak observed to the mass of its corresponding primary amino acid sequence, i.e., nonglycosylated ß6-ß40. The presence of residual triantennary sugars on hCGßcf has not been as well determined as for free hCGß but should be characterized to determine any diagnostic potential. In this study, we used MALDI-TOF MS, for the first time, to directly observe and determine the number of glycoforms in a purified sample of pooled pregnancy hCGßcf.


   Materials and Methods
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
materials
The hCGßcf used in this study was isolated from crude urinary hCG (Sigma) and characterized previously (29). DTT, for the reduction of disulfide bonds, and NH4HCO3 were obtained from Sigma-Aldrich. The MALDI-TOF MS matrix 3,5-dimethoxy-4-hydroxycinnamic acid (sinapinic acid; SA) was also purchased from Sigma-Aldrich and used without further purification. Acetonitrile and trifluoroacetic acid (TFA) were of analytical grade and obtained from Merck.

maldi-tof ms
To acquire spectra of the nonreduced molecule, we applied 0.5 µL of hCGßcf [20 µmol/L in distilled, deionized H2O (dH2O)] to a stainless steel MALDI-TOF MS target and mixed it with 1.0 µL of SA [20 g/L in 70:30 (by volume) acetonitrile-1 mL/L TFA in dH2O] and air dried. The instrument was calibrated externally using horse heart cytochrome C (Mr 12 360.1; Sigma-Aldrich). Spectra of reduced glycoforms were obtained by first mixing, on a MALDI-TOF MS target, 0.5 µL of hCGßcf (20 µmol/L in dH2O) with 0.5 µL of DTT (100 mmol/L in 100 mmol/L NH4HCO3, pH 8.8) (30). When this mixture was virtually dry, 0.5 µL of 1 mL/L TFA in dH2O was added to the remaining droplet. After the mixture was again allowed to partially dry, 1.0 µL of SA [20 g/L in a 70:30 mixture (by volume) of acetonitrile-1 mL/L TFA in dH2O] was added, and the sample was air-dried as before. Mass spectrometric analysis was carried out on VG TofSpec E (Micromass) and LaserMAT 2000 (Finnigan MAT) instruments, with 1.5 m and 0.5 m flight tubes, respectively, and both operating at an accelerating voltage of 20 kV. A pulsed nitrogen laser ({lambda}max = 337 nm) was used to desorb ions from the samples, which were detected by a microchannel plate detector at a sampling rate of 500 MHz. Spectra were generated by summing 30–40 laser shots. Data were acquired from both instruments operating in the positive linear mode.

treatment of results
Initially, the peak relating to the nonglycosylated hCGßcf peptide (ß55-ß92) was internally calibrated to the average molecular mass of its given primary sequence, [M+H]+ 4156.8 (calculated using the Protein Abacus computer software; Finnigan MAT). This facilitated the automatic correction of the mass values of the remaining peaks to their correct values.

To determine the inferred mass values of the hCGßcf carbohydrate moieties, we subtracted the average molecular mass ([M+H]+ 3752.4) of the primary sequence of the glycosylated hCGßcf polypeptide (ß6-ß40) from the mass ([M+H]+) values of the acquired peaks (Table 1 ). The carbohydrate content of these peaks was then deduced by the sequential subtraction of the masses of the sugar residues present in hCG ß-subunit carbohydrates (Table 2 ). Carbohydrate structures (Table 3 ) could then be predicted from the deduced monosaccharide content, taking into account the very small difference between the calculated and the observed masses (<=0.15%). Different combinations of carbohydrate structures are shown where the mass of a peak indicated several monosaccharides from which several permutations could be construed. Although this study did not yield any conformational information, the anomeric glycosidic linkages within the carbohydrate structures in Table 3 have been described previously (14) and were used in our analysis.


View this table:
[in this window]
[in a new window]
 
Table 1. Peptides of hCGßcf released after DTT reduction, detected by MALDI-TOF MS.


View this table:
[in this window]
[in a new window]
 
Table 2. Relative molecular mass (RMM) of the monosaccharides expected to be present in hCGß subunit N-linked carbohydrates.


View this table:
[in this window]
[in a new window]
 
Table 3. Proposed structures of the oligosaccharides in the glycoforms contributing to the microheterogeneity of hCGßcf.1


   Results
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
SA was selected as the MALDI-TOF MS matrix of choice for this investigation because other standard matrices used in protein analysis, {alpha}-cyano-4-hydoxycinnamic acid and sDHB [a 9:1 (by weight) mixture of 2,5-dihydroxybenzoic acid and 5-methoxysalicylic acid], did not yield intense spectra for hCGßcf (data not shown). A typical spectrum of hCGßcf obtained by MALDI-TOF MS using SA is shown in Fig. 3 . The spectrum is characterized by a broad triple peak at m/z 8700–11300 with discernible peaks at m/z 9110, 9930, and 10770. After reduction with DTT (Fig. 4 ), the triple peak disappeared and was replaced by a set of resolved peaks between m/z 4156 and 6354. The initial peak (Fig. 4 ), at m/z 4164.2, was presumed to arise from the nonglycosylated hCGßcf peptide chain (ß55-ß92) because the m/z value is within the 0.5% error allowed for the linear mode of the MALDI instrument. To obtain corrected values for the remaining peaks, this peak was internally calibrated to the average molecular mass of the given primary sequence, [M+H]+ 4156.8 (calculated using the Protein Abacus computer software). Despite the fact that hCGßcf asparagine-linked carbohydrate moieties were not observed directly, the low percentage errors between the observed and the expected mass values of the peaks acquired show that it is likely that real glycoforms were detected (Table 1Up ).



View larger version (12K):
[in this window]
[in a new window]
 
Figure 3. MALDI-TOF mass spectrum of purified hCGßcf in SA matrix generated by summation of the signals from 40 laser shots and calibrated externally using horse heart cytochrome C (Mr 12 360.1).



View larger version (17K):
[in this window]
[in a new window]
 
Figure 4. MALDI-TOF mass spectrum of hCGßcf after "on-target" DTT reduction and using SA matrix.

The spectrum was generated by summation of the signals from 30 laser shots and calibrated internally using fragment mass [M+H]+ 4156.8. Peaks 1–9 are described in the text.

Carbohydrate moieties, shown in Table 3Up , were determined as described above. Peak 1 (m/z 4630.2) arises from a polypeptide possessing a single truncated and fucosylated monoantennary oligosaccharide (Man2GlcNAc2Fuc) with a predicted mass of 876.8, whereas the polypeptide giving rise to peak 2 (m/z 4819.6) has two shortened fucosylated monoantennary sugars (ManGlcNAc2Fuc and GlcNAc2Fuc) with a predicted mass of 1064.0. Peaks 6 (m/z 5677.9) and 7 (m/z 5821.1) apparently arise from hCGßcf glycoforms containing two N-linked trimannosyl core carbohydrates (Man3GlcNAc2). In peak 6, a single trimannosyl core possesses fucose (with a predicted mass of 1931.8), whereas both are fucosylated in peak 7 (with a predicted mass of 2077.9). The combination of monosaccharide residues (with a predicted mass of 2420.3) that make up the glycoform observed at peak 8 (m/z 6179.0) can be configured to produce an identical pair of sugar structures that are shortened versions (GlcNAc2Man2GlcNAc2) of carbohydrate structures II or IV found by Elliott et al. (14). The number of monosaccharide residues calculated for the polypeptides giving mass spectral peaks 3–5 and peak 9 precludes the determination of a single pair of glycoforms, and for these alternative structures have been suggested. The predicted mass of 1242.2 for the carbohydrate moiety of the glycoform at peak 3 (m/z 5000.8) indicates either a single fucosylated trimannosyl core attached to a monoantennary N-acetylglucosamine (Man3GlcNAc3Fuc) or a trimannosyl core (Man3GlcNAc2) at one glycosylation site and a single GlcNAc at the other, one of which is fucosylated. Peak 4 (m/z 5358.2) indicates a glycoform with a predicted carbohydrate mass of 1607.5, which can translate to two shortened core sugars (Man2GlcNAc2) differing by a fucose residue. An alternative combination includes a trimannosyl core and a shortened core (ManGlcNAc2), one of which is fucosylated. Similarly, the predicted carbohydrate mass (1769.6) for the glycoform seen at peak 5 (m/z 5517.6) indicates a monosaccharide content from which may be constructed a trimannosyl core (Man3GlcNAc2) and a truncated core oligosaccharide (Man2GlcNAc2), one of which is connected to a fucose residue. Finally, two extended trimannosyl cores (Man3GlcNAc4) can be inferred from a predicted carbohydrate mass of 2598.4 of the glycopeptide at peak 9 (m/z 6353.8). Structures construed from this mass may be pairs or a combination of truncated oligosaccharides II, III, or IV in Fig. 1Up . There is an additional peak in the mass spectra of DTT-reduced hCGßcf between peaks 3 and 4 that we assume to be an additional glycoform but for which the data analysis software was unable to acquire a value.


   Discussion
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 
Direct carbohydrate analyses of hCGßcf in previous studies have generally suggested that the metabolite retains shortened hCGß asparagine-linked oligosaccharides that have been trimmed back to their trimannosyl cores and smaller sugars (22)(23)(24)(25)(26). In addition, de Medeiros et al. (24) found that 22–44% of hCGßcf molecules were not bound by the lectin concanavalin A, and of those 88% were completely deprived of any carbohydrate content. After DTT reduction, our MALDI-TOF MS data indicated the presence of only one nonglycosylated peptide at m/z 4156.8 within the dipeptide molecule. If the usually glycosylated peptide (ß6-ß40) had been completely lacking in carbohydrate, then a peak at m/z 3752.4 should have been apparent in the mass spectrum of reduced hCGßcf. This peak was not observed at all in any of the spectra acquired from reduced hCGßcf. Additionally, our MALDI analysis of hCGßcf confirms the lack of sialic acid as expected but also the lack of any galactose in this preparation.

The galactose content of hCGßcf has been reported differently. Direct carbohydrate analyses after acid hydrolysis (24) or conversion of sugars to glycamines (23) has detected small amounts of galactose. Conversely, indirect analysis has found hCGßcf N-linked sugars lacking in the monosaccharide (22)(25). The observation that hCGßcf is not bound by galactose-specific Ricinus communis agglutinin-agarose affinity matrix (23)(25) has been attributed to the inability of the matrix to bind one galactose residue per N-linked sugar, whereas contaminating glycoprotein is thought to account for hCGßcf galactose detected directly (22). This direct MALDI-TOF MS analysis indicated that no galactose was present in the N-linked sugars of the sample we investigated. It is uncertain where the degradation of hCG carbohydrates occurs. In their study of hCGß separated from intact urinary hCG, Liu and Bowers (7) detected a range of both sialated and asialo mono-, bi-, and triantennary N-linked oligosaccharides. It would therefore seem likely that the majority of sialic acid and galactose residues are lost as hCG is processed to hCGßcf after renal reabsorption. Whether or not this is the case, our results indicate that hCGßcf possesses neither sialic acid nor galactose residues. In fact, the glycoforms that appear to be present in hCGßcf range from a single GlcNAc residue to more complex structures extending beyond the trimannosyl core. The largest carbohydrate structures inferred by our results, peaks 8 and 9 in Fig. 4Up , may arise from degraded forms of the sugars II and IV in Fig. 1Up , determined by Elliott et al. (14) in hCGß.

Absolute quantification of the relative amounts of each N-linked carbohydrate moiety was not possible using this method. Semiquantification of relative amounts of glycoform pairs was possible by determining the areas under the peaks of the reduced peptides. Unfortunately, many peaks could have arisen from multiple combinations of sugars. However, the monosaccharides determined from peak 8 (see Table 3Up ) give rise to a combination of only two carbohydrates moieties that may arise from shortened triantennary oligosaccharides. This peak comprised 15.6% of the carbohydrate content of this sample, which is in agreement with the triantennary content of normal pregnancy hCG ß-subunits as determined by Elliott et al. (14). Because the crude preparation from which this hCGßcf was prepared may have contained urinary hCGß from not necessarily normal pregnancies, it is impossible to say whether the larger sugar moieties we observed originated from either the triantennary carbohydrate (IV in Fig. 1Up ) seen in normal or aberrant pregnancies or the biantennary sugar (II in Fig. 1Up ) observed almost exclusively in gestational diabetes (14).

In conclusion, the percentage abundance of other glycoforms detected by MALDI-TOF MS indicates that it is likely that the microheterogeneity of the hCGß N-linked carbohydrates found by Elliott et al. (14) is conserved in hCG ß-core fragments from all normal and aberrant pregnancies. Although not precisely defining hCGßcf glycosylation, the MALDI-TOF mass spectrum of DTT-reduced hCGßcf produces what appears to be a distinctive "fingerprint". For example, peaks of higher mass attributable to the increased triantennary sugar content of hCGßcf would be expected to increase in area in the spectra of hCG ß-core fragments from individuals with abnormal or Down syndrome pregnancies and choriocarcinoma. Until now, definitive testing for hyperglycosylation in hCG in patient urine has required multiple precipitation and chromatographic steps (31) followed by thiol reduction, glycan release, and HPLC (14). This is an approach that may be considered too time-consuming for routine clinical biochemistry. Although an extract of hCGßcf was analyzed in our current investigation, MALDI-TOF MS analysis of unextracted urine samples from pregnant women shows a broad peak corresponding to protonated hCGßcf, indicating that its concentration in pregnancy urine is sufficiently high for detection purposes. Further study will help to elucidate whether the reductive technique described here can be applied to pregnancy or choriocarcinoma urine, possibly after desalting and concentration by centrifugal ultrafiltration (10). The potential clinical utility for distinguishing between normal pregnancy and Down syndrome pregnancy by this approach needs to be demonstrated and is currently under investigation.


   Acknowledgments
 
This ongoing project is funded by the Joint Research Board of St. Bartholomew’s Hospital, London.


   Footnotes
 
1 Nonstandard abbreviations: hCG, human chorionic gonadotropin; hCGß, hCG ß-subunit; DTT, dithiothreitol; MALDI-TOF MS, matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; hCGßcf, hCG ß-core fragment; SA, sinapinic acid; TFA, trifluoroacetic acid; dH2O, distilled, deionized water; and GlcNAc, N-acetylglucosamine.


   References
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
 

  1. Laidler P, Cowan DA, Hider RC, Kicman AT. New decision limits and quality-control material for detecting human chorionic gonadotropin misuse in sports. Clin Chem 1994;40:1306-1311.[Abstract/Free Full Text]
  2. Cole LA, Wang Y, Elliott M, Latif M, Chambers JT, Chambers SK, Schwartz PE. Urinary human chorionic gonadotropin free ß-subunit and core fragment: a new marker of gynecological cancers. Cancer Res 1988;48:1356-1360.[Abstract/Free Full Text]
  3. Iles RK, Chard T. Immunochemical analysis of the human chorionic gonadotrophin-like material secreted by ‘normal’ and neoplastic urothelial cells. J Mol Endocrinol 1989;2:107-112.[Abstract/Free Full Text]
  4. Gillott DJ, Iles RK, Chard T. The effects of ßhCG on the in vitro growth of bladder cancer cells. Br J Cancer 1996;73:323-326.[ISI][Medline] [Order article via Infotrieve]
  5. Butler SA, Ikram MS, Mathieu S, Iles RK. The increase in bladder carcinoma cell population induced by the free beta subunit of human chorionic gonadotrophin is a result of an anti-apoptosis effect and not cell proliferation. Br J Cancer 2000;82:1553-1556.[ISI][Medline] [Order article via Infotrieve]
  6. Liu C, Bowers LD. Mass spectrometric characterization of the beta-subunit of human chorionic gonadotropin. J Mass Spectrom 1997;32:33-42.[ISI][Medline] [Order article via Infotrieve]
  7. Liu C, Bowers LD. Mass spectrometric characterization of nicked fragments of the ß-subunit of human chorionic gonadotrophin. Clin Chem 1997;43:1172-1181.[Abstract/Free Full Text]
  8. Lapthorn AJ, Harris DC, Littlejohn A, Lustbader JW, Canfield RE, Machin KJ, et al. Crystal structure of human chorionic gonadotropin. Nature 1994;369:455-461.[Medline] [Order article via Infotrieve]
  9. Wu H, Lustbader JW, Liu Y, Canfield RE, Hendrickson WA. Structure of human chorionic gonadotropin at 2.6 Å resolution from MAD analysis of the selenomethionyl protein. Structure 1994;2:545-558.[Medline] [Order article via Infotrieve]
  10. Laidler P, Cowan DA, Hider RC, Keane A, Kicman AT. Tryptic mapping of human chorionic gonadotropin by matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun Mass Spectrom 1995;9:1021-1026.[ISI][Medline] [Order article via Infotrieve]
  11. Liu C, Bowers LD. Immunoaffinity trapping of urinary human chorionic gonadotropin and its high-performance liquid chromatographic-mass spectrometric confirmation. J Chromatogr B Biomed Appl 1996;687:213-220.[Medline] [Order article via Infotrieve]
  12. Kessler MJ, Reddy MS, Shah RH, Bahl OP. Structures of N-glycosidic carbohydrate units of human chorionic gonadotropin. J Biol Chem 1979;254:7901-7908.[Free Full Text]
  13. Damm JBL, Voshol H, Hard K, Kamerling JP, Van Dedem GWK, Vliegenthart JFG. The ß-subunit of human chorionic gonadotropin contains N-glycosidic trisialo tri-antennary and tri’-antennary carbohydrate chains. Glycoconjugate J 1988;5:221-233.
  14. Elliot MM, Kardana A, Lustbader JW, Cole LA. Carbohydrate and peptide structure of the {alpha}- and ß-subunits of human chorionic gonadotropin from normal and aberrant pregnancy and choriocarcinoma. Endocrine 1997;7:15-32.[ISI][Medline] [Order article via Infotrieve]
  15. Kobata A. Altered glycosylation of human chorionic gonadotropin in malignant trophoblastic diseases. Mochizuki M Hussa R eds. Placental protein hormones 1988:133-142 Elsevier Amsterdam. .
  16. Mizuochi T, Nishimura R, Derappe C, Taniguchi T, Hamamoto T, Mochizuki M, Kobata A. Structures of the asparagine-linked sugar chains of human chorionic gonadotropin produced in choriocarcinoma. J Biol Chem 1983;258:14126-14129.[Abstract/Free Full Text]
  17. Yoshimoto Y, Wolfsen AR, Odell WD. Glycosylation, a variable in hCG production by cancers. Am J Med 1979;67:414-420.[ISI][Medline] [Order article via Infotrieve]
  18. Cole LA, Cermik D, Bahado-Singh R. Oligosaccharide variants of hCG-related molecules: potential screening markers for Down syndrome [Letter]. Prenat Diagn 1997;17:1187-1190.[ISI][Medline] [Order article via Infotrieve]
  19. Birken S, Krichevsky A, O’Connor J, Schlatterer J, Cole L, Kardana A, Canfield R. Development and characterization of antibodies to a nicked and hyperglycosylated form of hCG from a choriocarcinoma patient. Endocrine 1999;10:137-144.[ISI][Medline] [Order article via Infotrieve]
  20. Cole LA, Omrani A, Cermik D, Bahado-Singh RO, Mahoney MJ. Hyperglycosylated hCG, a potential alternative to hCG in Down syndrome screening. Prenat Diagn 1998;18:926-933.[ISI][Medline] [Order article via Infotrieve]
  21. Cole LA, Shahabi S, Oz UA, Rinne KM, Omrani A, Bahado-Singh RO, Mahoney MJ. Urinary screening tests for fetal Down syndrome. II. Hyperglycosylated hCG. Prenat Diagn 1999;19:351-359.[ISI][Medline] [Order article via Infotrieve]
  22. Endo T, Nishimura R, Saito S, Kanazawa K, Numura K, Katsuno M, et al. Carbohydrate structures of ß-core fragment of human chorionic gonadotropin isolated from a pregnant individual. Endocrinology 1992;130:2052-2058.[Abstract]
  23. Birken S, Armstrong EG, Kolks MAG, Cole LA, Agosto GM, Krichevsky A, et al. Structure of the human chorionic gonadotropin ßsubunit fragment from pregnancy urine. Endocrinology 1988;123:572-583.[Abstract]
  24. de Medeiros SF, Amato F, Matthews CD, Norman RJ. Molecular heterogeneity of the ß-core fragment of human chorionic gonadotrophin. J Endocrinol 1993;139:519-532.[Abstract/Free Full Text]
  25. Blithe DL, Akar AH, Wehmann RE, Nisula BC. Purification of ß-core fragment from pregnancy urine and demonstration that its carbohydrate moieties differ from those of native human chorionic gonadotropin-ß. Endocrinology 1988;122:173-180.[Abstract]
  26. Blithe DL, Wehmann RE, Nisula BC. Carbohydrate composition of ß-core. Endocrinology 1989;125:2267-2272.[Abstract]
  27. Karas M, Hillenkamp F. Laser desorption ionisation of proteins with molecular masses in excess of 10000 daltons. Anal Chem 1988;60:2299-2301.[Medline] [Order article via Infotrieve]
  28. Sutton C, O’Neill JA, Cottrell JS. Site-specific characterization of glycoprotein carbohydrates by exoglycosidase digestion and laser desorption mass spectrometry. Anal Biochem 1994;218:34-36.[ISI][Medline] [Order article via Infotrieve]
  29. Lee CL, Iles RK, Shepherd JH, Hudson CN, Chard T. The purification and development of a radioimmunoassay for ß-core fragment of a human chorionic gonadotrophin in urine: application of a marker of gynaecological cancer in premenopausal and postmenopausal women. J Endocrinol 1991;130:481-489.[Abstract/Free Full Text]
  30. Kussmann M, Nordhoff E, Rahbek-Nielsen H, Haebel S, Rossel-Larsen M, Jakobsen L, et al. Matrix-assisted laser desorption/ionization mass spectrometry sample preparation techniques designed for various peptide and protein analytes. J Mass Spectrom 1997;32:593-601.
  31. Kardana A, Elliott MM, Gawinowicz MA, Birken S, Cole LA. The heterogeneity of human chorionic gonadotropin (hCG). I. Characterization of peptide heterogeneity in 13 individual preparations of hCG. Endocrinology 1991;129:1541-1550.[Abstract]



The following articles in journals at HighWire Press have cited this article:


Home page
GlycobiologyHome page
L. Valmu, H. Alfthan, K. Hotakainen, S. Birken, and U.-H. Stenman
Site-specific glycan analysis of human chorionic gonadotropin {beta}-subunit from malignancies and pregnancy by liquid chromatography--electrospray mass spectrometry
Glycobiology, December 1, 2006; 16(12): 1207 - 1218.
[Abstract] [Full Text] [PDF]


Home page
Hum Reprod UpdateHome page
U.-H. Stenman, A. Tiitinen, H. Alfthan, and L. Valmu
The classification, functions and clinical use of different isoforms of HCG
Hum. Reprod. Update, November 1, 2006; 12(6): 769 - 784.
[Abstract] [Full Text] [PDF]


Home page
GlycobiologyHome page
A. Gervais, Y.-a. Hammel, S. Pelloux, P. Lepage, G. Baer, N. Carte, O. Sorokine, J.-m. Strub, R. Koerner, E. Leize, et al.
Glycosylation of human recombinant gonadotrophins: characterization and batch-to-batch consistency
Glycobiology, March 1, 2003; 13(3): 179 - 189.
[Abstract] [Full Text] [PDF]


This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Submit an electronic Letter to
the Editor about this paper
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (11)
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jacoby, E. S.
Right arrow Articles by Iles, R. K.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jacoby, E. S.
Right arrow Articles by Iles, R. K.
Related Collections
Right arrow Proteomics and Protein Markers
Right arrow Endocrinology and Metabolism


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS